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Caring for hepatitis C patients: Reflections on pharmacy and anthropology  
 
Richard H. Parrish II, BSPharm, PhD 
 
 
The cultural meaning of drug use deserves more attention in 
clinical pharmacy practice and research. Worldview and life 
experiences can alter pharmacotherapeutic responses 
because what patients believe about their medications – 
within the context of their lives -- will influence medication 
use and assessment of response.  Likewise, as evidenced by 
current patient safety initiatives, drug therapy systems can 
affect individual and population health. This connection 
between anthropology and drug therapy is seldom explored 
within the clinical context. Medication use is not random 
behavior. People make everyday sense of their drug therapies 
in some, often unique, ways.  By making sense, emotional, 
cultural, psychosocial, and interpersonal nuance and 
significance is attached to the use of medicines.  Moreover, 
medications are cultural symbols charged with meaning, 
accessed through a set of rituals, and managed in the context 
of individual life-worlds.  To illustrate anthropology in action 
from a pharmacotherapy perspective, I describe my work 
with patients with hepatitis C, the most common chronic 
blood-borne infection in the United States, and present 
common themes that patients express during private direct 
care encounters. 
 
“I never had any symptoms of disease.” 
 When I sit and listen with them, many of these 
patients say that they never had any symptoms of illness, and 
found out they had “the virus” on a routine check of blood 
chemistry.  Often, the source and duration of infection is 
unknown. As one patient said, “I wanted to have everyone I 
knew tested to make sure they were not infected. Just 
because you don’t have any symptoms doesn’t mean you 
don’t have the virus.” If the source is known, many patients 
express guilt over their indiscriminant exposure to the virus. 
Their attention immediately turns to family or friends who 
might have contracted the virus from them.   
I know where I got hepatitis C. I used 
heroin in the ‘70s, but have been clean 
for over 20 years. I was in and out of 
prison during that time, and didn’t 
really take any good care of myself. 
 
 
Corresponding Author:  Richard H. Parrish II, Director, 
Pharmacy Clinical Services and Residency Programs 
Division of Pharmacy, Children’s National Medical Center 
111 Michigan Avenue, NW, Room M4848, 4th floor 
Washington, DC  20010 
“Just give me the facts”  
Misinformation about hepatitis is rampant in the 
general population.  Many patients do not know what to 
think about the diagnosis, and begin to isolate themselves 
from their everyday worlds.  To appreciate what hepatitis C 
patients experience initially after identification of hepatitis C 
antigen and diagnosis of active disease, it can be thought of 
as related to the grieving process.  There is a sudden loss of 
self that comes from learning one has a chronic infectious 
disease, the fear of its impact on family and relationships, and 
the negotiation of changing life circumstances.  Sources of 
information about hepatitis C for the newly diagnosed patient 
are conflicting and overwhelming. 
Patients want the facts about the disease, their 
treatment options, and the impact of treatment on both the 
virus and them. “What is this going to do to me?” is a 
common question. Some patients have friends who have 
undertaken treatment 
 
“These meds are changing who I am.” 
For Jeff, anger, irritability, and hostility dominated 
his course of treatment.  His young children actually helped 
Jeff make the connection between his irritability and lack of 
water consumption.  “I was a rebel as a youngster, and got 
this tattoo in jail after a drunken binge.”  His chief physical 
complaint was the shortness of breath he noticed due the 
nature of his work; he climbed telephone poles for a living.  I 
saw him and his wife on several occasions to discuss the 
implications of the virus within their family.  When his 6-
month viral load returned unchanged, I really thought he 
would blame me.  In concert with my collaborator, (Jeff 
wanted me there with him for his appointment) we discussed 
options for continued treatment in a protocol for non-
responders.   However, due to a long travel distance and the 
potential impact on his work, he declined, saying he didn’t 
think the virus would kill him anyway.  He gave the virus his 
best shot, and thanked me for my care. 
 
“I’m sick all of the time.” 
 Once they get over the “treatment hump” (which 
varies for each patient, but seems to take from 6 weeks to 3 
months), long-term issues begin to emerge as well as queries 
related to their initial information overload. “What does the 
viral load mean?”  “Is my liver getting better?”  “What are my 
chances of ridding me of the virus?”  “Are my spouse and 
children at-risk from my hepatitis C?”  Often, patients 
become depressed (expressions of pain, anger, and 
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sleeplessness as well as sadness are common) from either 
dealing with the virus and/or the treatment.  Then, they 
usually get used to the somatic effects of the medications, 
unless dosage adjustments are needed due to low blood cell 
counts (platelets, white cells, and/or red cells).  For many, 
dosage adjustments are an indication to them of potential 
therapeutic failure, and can invoke fear and heighten anxiety.  
Adjustments can also be problematic because many patients 
have feelings as they did at the beginning of treatment (flu-
like symptoms, headache, and fatigue).  Some express anger 
at having their doses reduced because it decreases the virus’s 
exposure to drug.  They perceive and express this as failure.  
Constant reassurance is necessary to keep the patient 
engaged in the plan.  Often, normal stresses in life are 
magnified because the medication can increase irritability.  
Near the end, many patients express a lack of motivation to 
complete treatment.  They are tired of twice-daily capsule 
administration and weekly injections.  For many patients, 
timing of their final medication supply order is fraught with 
over-supply or under-supply. 
 
“Since I have no virus in my blood, I can stop treatment, 
right?” 
Another patient, Larry, a treatment naïve middle-
aged man, at first did not want anyone in his family to know 
he was taking treatment.   “No one knows now, and no one 
will ever know I’m taking treatment.”  I never understood 
why except that he preferred to solve his problems without 
family help.  Later, I realized that he never received much 
help in his family of origin.  His parents (deceased) as well as 
he and his sister had alcoholism and suffered a great deal of 
physical abuse from each other.   During treatment, he 
learned that his sister was positive for hepatitis C.  He prayed 
right before he gave his first injection of interferon in the 
office.  His greatest concerns stemmed from making sure he 
understood what the viral load meant so that he could 
minimize both future side effects and insurance expense.  We 
needed to return to this issue monthly, especially when his 
result was undetectable at 6 months because he wanted to 
stop treatment.  He weighed his persistent shortness of 
breath against the benefits of sustained viral response (an 
undetectable viral load 6 months after stopping treatment), 
and decided to continue each month until finished.  However, 
he made this decision every month after weighing the 
evidence at hand. 
 
“I was ready of punch out the guy’s lights.” 
My first patient, Kevin, was a relapsing, treatment-
experienced middle-aged businessman with a ten-year 
history of active disease.  This was his third time to begin 
therapy, this time with combined pegylated interferon (long 
acting) and ribavirin.  He kept a journal of events, thoughts, 
and feelings that he shared with me as part of our plan.  In 
the journal, he described the effects of his treatment in his 
relationships at work and home, and with his wife and 
relatives.  Much of his self-observation described his level of 
energy and motivation.  “Difficult to concentrate at work.  
Thought about hiring others to calculate job quotations.”  He 
used the journal to get through the first several months of 
treatment, and thought writing very therapeutic for him.  
During his course, he had several episodes of shingles and 
neutropenia (low white blood cell count), and persistent 
headaches, all that required medical management.  His 
interferon dosage was reduced because of his low count until 
he received blood cell growth stimulating factors.  The virus 
was undetectable in his blood at 6 months, a positive sign 
that he may not relapse (he wants to re-test his viral load 
when he feels badly, not at the usual 6 month post-
treatment).  He has regained weight and pre-treatment 
activity levels, and no longer struggles with insomnia or 
depression.  He became a trained facilitator for the local 
hepatitis support group, and now provides invaluable insights 
to others struggling with the virus or contemplating its 
treatment. 
 
“I want to cure this thing this time. Let’s be as aggressive as 
possible with the doses.” 
John was anxious about treatment from the 
beginning.  He had enrolled in a protocol for hepatitis C, but 
developed anemia and stopped treatment.  He has been 
married for 12 years, and has four children under age 11.  His 
treatment is complicated by his obesity; he weighed over 350 
pounds at treatment initiation.  He also wanted to loose 
weight as well.  We made and received a special appeal to 
Medicaid for a weight-based dosage regimen (we both 
agreed to be aggressive with treatment) because the 
scientific literature revealed poorer outcomes for obese 
patients with fixed doses.  His major reason for beginning 
treatment was he wanted to be around for his children.  
“Let’s be aggressive with the treatment and push the doses as 
high as possible.  I’ll take however much I can stand.”  On 
initiation of treatment, his level of anxiety was compounded 
by side affects (peripheral tingling, shortness of breath, and 
sexual problems).  I advocated for him with his other medical 
providers, and kept them in contact via my progress notes.  I 
received a page from Jon on a weekly basis until he 
reconnected with his extended family in Rhode Island.  He 
told me that an uncle had taken interferon for cancer, and 
drank a lot of water to feel better, which Jon and I discussed 
on every visit.  He had made it over the treatment hump, and 
decided that the most important thing for him to do was to 
“kill the virus.” He would stop worrying about his sexual 
problems, his alopecia, and his blood pressure (Stage 2).  
However, we needed to negotiate his ribavirin dose due to 
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incessant peripheral tingling.  According to the literature, 
1200 mg daily was his “ideal” dose.  According to the 
patient’s level of tolerance, 800 mg was the maximum he 
could take.  A dose of 600 mg was my minimum.  He 
regulated it between 600 mg and 1000 mg depending on how 
he felt. At month five, he developed an exacerbation of 
asthma that prompted an early determination of viral load.  
Unfortunately, he did not respond despite adhering as best as 
he could to therapy. 
 
Recommendation 
While the promises of a cure range between 45 and 75%, 
infection with the hepatitis C virus and its treatment place 
many challenges to everyday living. Like those living with 
cancers, patients medicating with pegylated interferon and 
ribavirin often feel much worse than the disease itself. Sitting 
with and listening to these patients can provide the clinician 
with an enhanced understanding of the patients’ medicating 
experience and a more enriched meaning above and beyond 
the histology, biochemistry, hematology, and virology of the 
disease. More observational and interview studies are 
needed that bring pharmacy and anthropology in closer 
proximity to inform and contextualize the meanings of 
medication use in modern societies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
